Objective? To observe the effects of Shuganning on negative emotion, sleeping quality and serum aspartate aminotransferase (AST), total bilirubin (TBIL) and alanine aminotransferase (ALT) levels of patients with chronic viral hepatitis B. Methods A total of 60 patients with chronic viral hepatitis B admitted to Huidong People's Hospital from May 2018 to May 2020 were selected and divided into the control group (30 cases) and the observation group (30 cases) according to the random number table. The control group was treated with Enticavir dispersive tablets, and the observation group was treated with Shuganning injection on the basis of the control group. Patients in both groups were treated continuously for 4 months. Clinical efficacy and Self-rating Depression Scale (SDS), Self-rating Anxiety Scale (SAS), Pittsburgh Sleep Quality Index (PSQI) scores, liver function indexes of patients before and after treatment, and the incidence of adverse reactions during treatment were compared between the two groups. Results? The total effective rate of observation group (96.67%) after treatment was higher than that of control group (80.00%); After treatment, the SDS, SAS, PSQI scores and serum AST, TBil, ALT levels of patients in the two groups decreased significantly compared with before treatment, and the observation group was lower than the control group; The total incidence of adverse events during treatment in the observation group was lower than that of the control group (all P <0.05). Conclusion? The application of Shuganning in the treatment of patients with chronic viral hepatitis B can effectively enhance the clinical treatment effect, improve the liver function, relieve negative emotions, improve the quality of sleep, and the safety is higher.